<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81570">
  <stage>Registered</stage>
  <submitdate>28/08/2006</submitdate>
  <approvaldate>29/08/2006</approvaldate>
  <actrnumber>ACTRN12606000381583</actrnumber>
  <trial_identification>
    <studytitle>An Open-Label Study Evaluating the Antiviral Activity of Tenofovir Disoproxil Fumarate (DF) 300mg in Patients with Chronic Hepatitis B Infection and Persistent Viral Replication after Long-Term Therapy with Adefovir Dipivoxil 10mg Daily</studytitle>
    <scientifictitle>An Open-Label Study Evaluating the Antiviral Activity of Tenofovir Disoproxil Fumarate (DF) 300mg in Patients with Chronic Hepatitis B Infection and Persistent Viral Replication after Long-Term Therapy with Adefovir Dipivoxil 10mg Daily</scientifictitle>
    <utrn />
    <trialacronym>109</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment for patients who are no longer responding to current, registered treatments (lamivudine 100 mgs daily and adefovir 10 mgs daily)
The drug is tenofovir, at 300 mgs orally daily. Treatment is given indefinitely.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the antiviral activity of tenofovir 300 mgs</outcome>
      <timepoint>At week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the safety and efficacy of tenofovir Disoproxil Fumarate (DF) 300mg daily.</outcome>
      <timepoint>At Week 48 and every 48 weeks thereafter to end of study (week 144).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the efficacy of tenofovir DF 300mg in patients with confirmed adefovir dipivoxil resistance (N236T and / or A181V-these are particular areas of the hepatitis B genome ).</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the incidence of tenofovir Disoproxil Fumarate (TDF) resistant mutations.</outcome>
      <timepoint>At Week 48 and at end of every 48 weeks therafter until end of study (Week 144).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the activity of combination therapy (tenofovir DF 300mg + lamivudine 100mg) in patients with with persistent viral replication following switch to tenofovir DF 300mg (defined as hepatitis B virus deoxyribonucleic acid (HBV DNA) ³400 copies/mL confirmed on 2 consecutive visits following at least 24 weeks treatment with tenofovir DF 300mg).</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male and non-pregnant/non-lactating female HBV infected patients. Patients who are currently receiving adefovir dipivoxil 10 mg daily in combination with lamivudine will be eligible for enrollment. Inclusion criteria include:·Chronic hepatitis B infection defined by positive serum hepatitis B surface antigen (HBsAg) for at least 6 months· Failed lamivudine therapy;· Active chronic hepatitis B infection:o hepatitis B E  antigen (HBeAg) negative OR HBeAg positiveo Serum HBV DNA greater or equal to 105 (HBeAg positive) or 104 (HBeAg negative) copies/ml at screening while receiving continuous therapy with adefovir dipivoxil 10mg daily for at least 24 weeks.· Written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Female who is pregnant or breastfeeding;· Female of childbearing potential who is unwilling to use effective contraception method while enrolled in the study;· Decompensated liver disease defined as bilirubin &gt; 1.5 times the upper limit of normal (ULN), prothrombin time (PT) &gt; 1.5 times the ULN, platelets &lt; 75,000/mm3, serum albumin &lt; 30g/l or prior history of clinical hepatic decompensation;· Evidence of hepatocellular carcinoma (alpha-fetoprotein &gt; 50mg/l);· Co-infection with hepatitis C virus (HCV),  human immunodeficiency virus (HIV) or hepatitis D virus (HDV);· Significant renal cardiovascular, pulmonary or neurological disease;· The following laboratory values obtained within 30 days prior to study entry:o Creatinine clearance &lt; 70 ml/mino haemoglobin (Hb) &lt; 8g/dlo Leukocytes &lt; 1000mm3.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health (investigator initiated)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Gilead</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Austin Health</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Monash Medical Centrre</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Alfred</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St Vincent's</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Melbourne</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Western hospital</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>RPA</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Gilead is a supporter of the study as they are supplying free drug</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the protocol is to provide people who not responding to current hepatitis B treatments another option.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/07/2006</ethicapprovaldate>
      <hrec>H2006/02552</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Peter Angus</name>
      <address>LTU, Austin Health, Studley Rd,
Heidelberg. 3084</address>
      <phone>03 9496 5582</phone>
      <fax>03 9496 2732</fax>
      <email>peter.angus@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Peter Angus</name>
      <address>LTU, Austin Health, Studley Rd,
Heidelberg. VIC 3084</address>
      <phone>03 9496 5582</phone>
      <fax>03 9496 2732</fax>
      <email>peter.angus@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>